Acute myeloid leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• FLT3 36
• TP53 9
• NPM1 27
• IDH 29
• KMT2A 20
• RUNX1 2
• CD123 19
• BCL-2 10
• ABL1 2
• CD33 17
• PI3K 3
• mTOR 0
• KIT 3
• JAK 1
• CD19 8
• MAPK 0
• STAT3 0
• ERK 0
• AKT 0
• CD38 6
• HDAC 2
• MYC 1
• NRF2 0
• PD-1 4
• PPAR 0
• CXCR4 0
• BRD4 0
• PD-L1 0
• RAS 0
• STING 1
• HIF-1 0
• TIM-3 0
• METTL3 0
• CD47 1
• CTNNB1 0
• JNK 0
• KRAS 0
• MEK 0
• PARP 3
• EZH2 0
• IL-6 2
• BRAF 0
• EGFR 0
• FTO 0
• HSP90 0
• PDGFR 0
• PTEN 0
• CDK4/6 0
• FGFR 2
• GPX4 0
• HMGB1 0
• NLRP3 0
• NRAS 0
• SHP2 0
• AMPK 0
• CD20 1
• IL-15 1
• MDM2 0
• PINK1 0
• PKM2 0

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Therapeutic restoration of CUX1 in -7/del(7q) acute myeloid leukemia

  University of Chicago· Chicago, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, United States· US$390,447 awarded in fiscal year 2026· until Aug 2031

• NIH NINDS · R03

  Uncovering glycoRNA landscape in glioblastoma as a novel layer of immune evasion

  University of Texas Hlth Sci Ctr Houston· Houston, United States· US$78,000 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R56

  Cooperation partners of SETBP1 in AML development

  Henry M. Jackson Fdn for the Adv Mil/Med· Bethesda, United States· US$149,152 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R21

  Loss of TET2 Promotes Leukemogenesis by Enhancing NPY-Mediated PRC2 Disruption and CTCFL Chromatin Remodeling

  Indiana University Indianapolis· Indianapolis, United States· US$407,543 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting EP300/CBP in AML: from mechanistic discovery to therapeutic innovation (EPIC-AML)

  Universita Degli Studi di Parma· Parma, Italy· EU contribution €193,643· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding the immuno-regulatory functions of the human bone marrow niche upon cancer cellular therapy (ImmunhOss)

  Lunds Universitet· Lund, Sweden· EU contribution €2,000,000· until Jan 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Targeting bioactive lipids to overcome leukemia immune evasion and improve allogeneic hematopoietic stem cell transplantation outcomes (LIFE)

  Universitat Basel· Basel, Switzerland· EU contribution €1,499,511· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Integrating DNA Methylation and Drug Abundance at Single-Cell Resolution to Predict Cancer Drug Sensitivity (EPI-SENSOR)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €1,499,423· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-ERC

  Perturbation-based Phosphoproteomics to Study Drug Response Heterogeneity (PerturbPhos)

  Universitatsklinikum Jena· Jena, Germany· EU contribution €1,491,735· until Sept 2031

  The disease is named only in the funder's project summary, not in the title.

10 of 499 running projects, newest first. Listed amounts together: US$310.8m + €53.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  CART-38 in Adult AML and MM Patients

  NCT05442580· University of Pennsylvania· Updated 26 Jun 2025

  “Administrative decision”Registry text, quoted unchanged. Source

• Terminated

  XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

  NCT05038644· Ehab L Atallah· Updated 8 May 2025

  “Drug expired May 31, 2024.”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML

  NCT06110208· 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China· Updated 26 Feb 2025

  “Collaborator's decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 39
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 17
• Gene Expression Profiling 85
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 7
• Exome Sequencing 1
• Proteomics 28
• Metabolomics 10
• Mass Spectrometry 3
• Flow Cytometry 88
• Immunohistochemistry 14
• Liquid Biopsy 1
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 160
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 11
• Machine Learning 33
• Deep Learning 12
• Cohort Studies 30
• Genome-Wide Association Study 3

• Protocol for isolation of lipid droplets and mitochondria from acute myeloid leukemia cells for lipidomic analysis.

  STAR Protoc, Dec 2025

• Comparative proteomic analysis of apoptosis induced by sodium selenite in human acute promyelocytic leukemia NB4 cells.

  J Cell Biochem, Aug 2006

• Metabolism of the vitamin D3 derivative (24R)-hydroxycalcidiol by human promyelocytic leukemia cells (HL-60). Isolation and identification of (5Z) and (5E)-(24R)-19-nor-10-oxo-24-hydroxycalcidiol.

  Eur J Biochem, Dec 1987

See which targets of this disease your abstract mentions, and go to the people working on them.